Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination In ≥ 50-year-old Adults

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2018 Dec 7

PMID 30518331

Citations 4

Authors

Joon Young Song

Hee Jin Cheong

Ji Yun Noh

Min Joo Choi

Jin Gu Yoon

Saem Na Lee

Seong Hui Kang

Eun Joo Jeong

Yu Mi Jo

Woo Joo Kim

Affiliations

Soon will be listed here.

Abstract

Background: When two or more vaccines are administered concurrently, there is concern about safety and immunogenicity from vaccine interaction.

Methods: Subjects aged ≥50 years were randomized 1:1:1 to receive tetanus-diphtheria (Td) + 13-valent pneumococcal conjugate vaccine (PCV13; Group 1), PCV13 alone (Group 2), or Td alone (Group 3). After single or concomitant vaccination, enzyme-linked immunosorbent assay and opsonophagocytic assay (OPA) were performed to compare immunogenicity for Td and PCV13, respectively.

Results: A total of 448 subjects were available for the assessment. After concomitant administration, the non-inferiority criteria of geometric mean titer (GMT) ratios were met for tetanus, diphtheria, and all four pneumococcal serotypes (1, 5, 18C, and 19A). However, subjects in Group 3 (Td alone) were more likely to have a high IgG anti-tetanus antibody titer (≥ 0.5 U/mL) than those in Group 1 (Td + PCV13) (p < 0.01). As for the pneumococcal serotype 1, the OPA GMT was significantly higher in Group 1 (PCV13 + Td) compared to Group 2 (PCV13 alone) (p = 0.02). No serious adverse event occurred.

Conclusions: Concomitant Td and PCV13 administration induced sufficient immunity without significant interference and showed good safety profiles.

Trials Registration: NCT03552445 registered at http://www.clinicaltrials.gov on June 11, 2018 (retrospectively registered).

Citing Articles

Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus.

Doroud D, Ashrafian F, Javadi A, Dahmardeh S, Banifazl M, Bavand A Vaccines (Basel). 2024; 12(3).

PMID: 38543877 PMC: 10974556. DOI: 10.3390/vaccines12030243.

Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making.

See K Vaccines (Basel). 2023; 11(5).

PMID: 37243012 PMC: 10223523. DOI: 10.3390/vaccines11050908.

Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco.

Abouqal R, Beji M, Chakroun M, Marhoum El Filali K, Rammaoui J, Zaghden H Front Public Health. 2022; 10:903376.

PMID: 35844850 PMC: 9286557. DOI: 10.3389/fpubh.2022.903376.

Clinical practice guidelines 2019: Indian consensus-based recommendations on pneumococcal vaccination for adults.

Dhar R, Ghoshal A, Guleria R, Sharma S, Kulkarni T, Swarnakar R Lung India. 2020; 37(Supplement):S19-S29.

PMID: 32830790 PMC: 7703813. DOI: 10.4103/lungindia.lungindia_272_20.

References

Greenberg D, Hoover P, Vesikari T, Peltier C, Hurley D, McFetridge R . Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018; 36(45):6883-6891. DOI: 10.1016/j.vaccine.2018.02.113. View

Schwarz T, Flamaing J, Rumke H, Penzes J, Juergens C, Wenz A . A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011; 29(32):5195-202. DOI: 10.1016/j.vaccine.2011.05.031. View

Tashani M, Alfelali M, Barasheed O, Alqahtani A, Heron L, Wong M . Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial. Vaccine. 2016; 34(48):5929-5937. DOI: 10.1016/j.vaccine.2016.10.020. View

Burton R, Nahm M . Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006; 13(9):1004-9. PMC: 1563573. DOI: 10.1128/CVI.00112-06. View

Tashani M, Heron L, Wong M, Rashid H, Booy R . Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. J Travel Med. 2017; 24(4). DOI: 10.1093/jtm/tax006. View

Choi J, Choo E, Huh A, Choi S, Eom J, Lee J . Immunogenicity and safety of diphtheria-tetanus vaccine in adults. J Korean Med Sci. 2010; 25(12):1727-32. PMC: 2995225. DOI: 10.3346/jkms.2010.25.12.1727. View

Granoff D, Rathore M, Holmes S, Granoff P, Lucas A . Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine. 1993; 11 Suppl 1:S46-51. DOI: 10.1016/0264-410x(93)90160-y. View

Frenck Jr R, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D . Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012; 19(8):1296-303. PMC: 3416075. DOI: 10.1128/CVI.00176-12. View

Ermlich S, Andrews C, Folkerth S, Rupp R, Greenberg D, McFetridge R . Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018; 36(45):6875-6882. DOI: 10.1016/j.vaccine.2018.03.012. View

10.

Borrow R, Dagan R, Zepp F, Hallander H, Poolman J . Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011; 10(11):1621-31. DOI: 10.1586/erv.11.142. View

11.

Dagan R, Poolman J, Siegrist C . Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010; 28(34):5513-23. DOI: 10.1016/j.vaccine.2010.06.026. View

12.

Song J, Cheong H, Hyun H, Seo Y, Lee J, Wie S . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults. Vaccine. 2016; 35(2):313-320. DOI: 10.1016/j.vaccine.2016.11.047. View

13.

CAIN H, FALCO F . Recurrent tetanus. Calif Med. 1962; 97:31-3. PMC: 1575104. View

14.

Amai M, Nojima M, Yuki Y, Kiyono H, Nagamura F . A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". Vaccine. 2023; 41(38):5622-5629. DOI: 10.1016/j.vaccine.2023.07.072. View

15.

Choi W, Choi J, Kwon K, Seo K, Kim M, Lee S . Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014. Infect Chemother. 2015; 47(1):68-79. PMC: 4384453. DOI: 10.3947/ic.2015.47.1.68. View

16.

Granoff D, Holmes S, Belshe R, Osterholm M, McHugh J, Anderson E . Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA. 1994; 272(14):1116-21. View

17.

Turner T, VELASCO-JOVEN E, Prudovsky S . Studies on the prophylaxis and treatment of tetanus. II. Studies pertaining to treatment. Bull Johns Hopkins Hosp. 1958; 102(2):71-84. View

18.

Pickering L, Baker C, Freed G, Gall S, Grogg S, Poland G . Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(6):817-40. DOI: 10.1086/605430. View